Welcome to our dedicated page for ADAPTIN BIO SEC filings (Ticker: APTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ADAPTIN BIO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ADAPTIN BIO's regulatory disclosures and financial reporting.
Adaptin Bio, Inc. filed an Amendment No. 1 to its annual report for the year ended December 31, 2025. The update is narrow and revises Item 15(b) and Exhibit 23.1 to provide an updated consent from WithumSmith+Brown, PC, its independent registered public accounting firm, to reference a company registration statement that was previously omitted.
The company states that no other financial or non-financial information from the original annual report has been changed and that the amendment does not reflect events occurring after the original filing. As of June 11, 2026, Adaptin Bio had 8,903,229 shares of common stock outstanding, and its non‑affiliate equity market value was approximately $9.3 million as of June 30, 2025.
Adaptin Bio, Inc. files a prospectus supplement updating its S-1 to register resale of 1,901,482 shares of common stock and notes 2,233,083 shares underlying warrants held by selling stockholders. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026, its Form 10-K for fiscal 2025 and an 8-K.
The Company reported $301,309 in cash as of March 31, 2026, a net loss of $1,146,096 for Q1 2026 and an accumulated deficit of $10,437,897. Shares outstanding were stated as 8,851,229 as of May 14, 2026. The supplement updates offering and disclosure materials and should be read with the underlying Prospectus.
Adaptin Bio, Inc. reported a Q1 2026 net loss of $1,146,096, wider than the prior-year loss of $603,084, as it increased investment in R&D and public-company overhead.
The company ended March 31, 2026 with cash and equivalents of $301,309 and an accumulated deficit of $10,437,897. Management disclosed that these conditions raise substantial doubt about its ability to continue as a going concern and expects to rely on additional equity or debt financings. During the quarter, Adaptin raised gross proceeds of $652,000 through its Follow-on Offering, issued 130,400 new shares, and continued advancing its APTN-101 brain cancer program while operating with a working capital deficit.